Search Result

Results for "

JAK-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (29) Apoptosis (9) Autophagy (6) Bacterial (2) FLT3 (2) Fungal (2) HDAC (1) Influenza Virus (2) Isotope-Labeled Compounds (1) Mitophagy (2) NF-κB (1) RIP kinase (1) STAT (2) STING (1) Syk (1)
By Research Areas:	Cancer (19) Infection (2) Inflammation/Immunology (12)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Targets Recommended: JAK AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13827

*JAK-IN-1* 1 Publications Verification	JAK	Inflammation/Immunology
JAK-IN-1 is a *JAK1/2/3* inhibitor with IC₅₀s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.

HY-50856

Ruxolitinib Maximum Cited Publications 117 Publications Verification INCB18424	JAK Autophagy Mitophagy Apoptosis	Cancer
Ruxolitinib (INCB18424) is a potent and selective *JAK1/2* inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .

HY-148785

Nimucitinib

JAK Others

Nimucitinib is a Janus kinase (JAK) inhibitor .
HY-145029

SYK/JAK-IN-1

Syk JAK Inflammation/Immunology Cancer

SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively ^[1].

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

SYK/JAK-IN-1	Syk JAK	Inflammation/Immunology Cancer
SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC₅₀s of <5 nM for SYK and JAK2, respectively ^[1].

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a JAK inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively ^[1].

HY-154969

JAK-IN-29

JAK Others

JAK-IN-29 (compound 3) is a potent JAK inhibitor .
HY-157011

JAK-IN-33

JAK Inflammation/Immunology

JAK-IN-33 (compound 3 (R)) is a JAK inhibitor .

JAK-IN-29	JAK	Others
JAK-IN-29 (compound 3) is a potent JAK inhibitor .

JAK-IN-33	JAK	Inflammation/Immunology
JAK-IN-33 (compound 3 (R)) is a *JAK* inhibitor .

HY-50859

Ruxolitinib sulfate INCB018424 sulfate	JAK Autophagy	Cancer
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective *JAK1/2* inhibitor to enter the clinic with IC₅₀s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.

HY-14986

JAK-IN-32

JAK Others

JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase .

JAK-IN-32	JAK	Others
JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase .

HY-109175

Fosifidancitinib	JAK	Inflammation/Immunology
Fosifidancitinib is a potent and selective inhibitor of *JAK kinases 1/3*. Fociatinib is used in studies of allergies, asthma and autoimmune diseases ^[1].

HY-50856A

Ruxolitinib (S enantiomer) 4 Publications Verification S-RuxolitINib; S-INCB18424	JAK	Cancer
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent *JAK* inhibitor .

HY-13961

GLPG0634 analog

JAK Cancer

GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-109178

Ifidancitinib ATI-50002; ATI-502	JAK	Others
Ifidancitinib (ATI-50002) is a potent and selective inhibitor of *JAK kinases 1/3*. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases ^[1].

HY-15315A

Baricitinib phosphate 35+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-40354A

Tofacitinib citrate 45+ Cited Publications TasocitINib citrate; CP-690550 citrate	JAK Apoptosis Bacterial Fungal Influenza Virus	Infection Inflammation/Immunology Cancer
Tofacitinib citrate is an orally available *JAK1/2/3* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-10963

Momelotinib Mesylate CYT387 Mesylate	JAK Autophagy	Cancer
Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

HY-10961

Momelotinib 10+ Cited Publications CYT387	JAK Autophagy Apoptosis	Cancer
Momelotinib (CYT387) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.

HY-50858

Ruxolitinib phosphate Maximum Cited Publications 117 Publications Verification INCB018424 phosphate	JAK Autophagy Mitophagy	Cancer
Ruxolitinib phosphate (INCB018424 phosphate) is a potent *JAK1/2* inhibitor with IC₅₀s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

HY-50856S

Deuruxolitinib CTP-543; RuxolitINib d₈; Deuterated RuxolitINib	JAK	Inflammation/Immunology
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of *JAK1/JAK2*. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) ^[1].

HY-10962

Momelotinib sulfate 10+ Cited Publications CYT387 sulfate salt	JAK Autophagy Apoptosis	Cancer
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of *JAK1/JAK2* with IC₅₀ of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC₅₀=155 nM).

HY-161060

Zharp1-211	RIP kinase	Inflammation/Immunology
Zharp1-211 is a potent inhibitor of RIPK1 kinase. Zharp1-211 significantly reduces the expression of *JAK/STAT1*-mediated chemokines and MHC class II molecules in intestinal epithelial cells ^[1].

HY-40354AS

Tofacitinib-d3 citrate TasocitINib-d₃ citrate; CP-690550-d₃ citrate	Isotope-Labeled Compounds JAK Apoptosis Bacterial Fungal Influenza Virus	Infection Inflammation/Immunology Cancer
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-14722A

NVP-BSK805 dihydrochloride 1 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively ^[1].

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively ^[1].

HY-14722

NVP-BSK805 1 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively ^[1].

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-125019

iJak-381	JAK STAT	Inflammation/Immunology
iJak-381 is a *JAK1/2* inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) ^[1].

HY-149283

JAK/HDAC-IN-2	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers ^[1].

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells ^[1] .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells ^[1] .

HY-13775

XL019 4 Publications Verification	JAK Apoptosis	Cancer
XL019 is a potent, orally active, and selective JAK2 inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-151262

JAK-IN-23	JAK STING NF-κB STAT	Inflammation/Immunology
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC₅₀ values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC₅₀ values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) ^[1].

JAK/STAT Compound Library	423 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 423 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of *JAK1/JAK2*. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) ^[1].

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: